Top Markets
Coin of the day
Accelerate Diagnostics, Inc. Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc.

AXDX
Rang in Aktien #40437
Accelerate Diagnostics, Inc. is an in vitro diagnostics company specializing in... Accelerate Diagnostics, Inc. is an in vitro diagnostics company specializing in solutions for the rapid diagnosis of critical infections, with operations spanning the United States, Europe, and the Middle East. The company's primary offering is the Accelerate Pheno system, an advanced in vitro diagnostic platform. Paired with its dedicated test kit, the Accelerate PhenoTest, this system facilitates quick identification and antimicrobial susceptibility testing (AST) for pathogens responsible for severe or healthcare-associated infections, encompassing both Gram-positive and Gram-negative organisms. The PhenoTest is specifically designed to yield crucial ID and AST results for patients suspected of bacteremia or fungemia – life-threatening conditions marked by high morbidity and mortality risks. Established in 1982, the company initially operated as Accelr8 Technology Corporation before adopting its current name, Accelerate Diagnostics, Inc., in December 2012. Its corporate headquarters are located in Tucson, Arizona.
Aktienkurs
$0.01005
Zuletzt synchronisiert: 2025-06-09
Marktkapitalisierung
$146.42K
Veränderung (1 Tag)
-28.21%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Accelerate Diagnostics, Inc. (AXDX)

Kategorie

EPS für Accelerate Diagnostics, Inc. (AXDX)
EPS zum 2026 TTM: 0
Laut den aktuellen Finanzberichten und dem Aktienkurs von Accelerate Diagnostics, Inc. beträgt das aktuelle EPS des Unternehmens (TTM) 0. Am Ende des Jahres 2026 betrug das EPS 0 gleich wie dem EPS von 2026, das 0 betrug.
EPS-Verlauf von Accelerate Diagnostics, Inc. von 2026 bis 2026
EPS am Ende jedes Jahres
Jahr EPS ändert
Nicht genügend Daten für die angegebenen Daten.
EPS für ähnliche Unternehmen oder Wettbewerber